Paragon Biosciences Names James Robinson President and Chief Operating Officer
The newly-created position is the result of rapid expansion at Paragon and its portfolio companies, which are developing novel medical treatments.
Jeff Aronin is Named Innovator of the Year by Best in Biz
With its highest honor, a Gold level award, Best in Biz recognizes Jeff Aronin for his lifelong commitment to developing breakthrough therapies for severe medical conditions.
Crain’s Chicago Business: “Chicago-based Biotech Incubator Raises $71.8 Million”
Paragon Biosciences CEO Jeff Aronin spoke with Crain’s Chicago Business on his role in the company, his vision for Paragon, and his mission to bring treatments to patients suffering from rare, genetic, debilitating diseases that too few companies focus on.
Paragon Biosciences Announces $71.8 Million in New Investment for Portfolio Company Castle Creek Pharma
Paragon Biosciences (Paragon) today announced the completion of a new capital investment of $71.8 million for Castle Creek Pharma (Castle Creek), a Paragon portfolio company.
Jeff Aronin Named One of the 20 Most Influential Leaders in Healthcare for 2018
Paragon Biosciences CEO Jeff Aronin was recognized this week by Insights Care magazine for his innovative leadership in the biosciences sector and for his work bringing life-altering drugs to patients in need.
Paragon Biosciences Announces Skyline Biosciences as the Newest Addition to Its Growing Portfolio of Companies
Paragon Biosciences (Paragon) today announced Skyline Biosciences (Skyline) as the newest addition to its growing portfolio of drug-development companies. Paragon identifies unmet patient needs, invests in the development of novel medicines, and incubates biopharmaceutical companies, such as Skyline.
Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome
Biopharmaceutical company Emalex Biosciences (Emalex), the newest member of the Paragon Biosciences (Paragon) portfolio of companies, today announced it acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register and market ecopipam, a new chemical entity with orphan drug designation for the treatment of pediatric Tourette Syndrome (TS) in patients under 16 years of age.
Castle Creek Pharmaceuticals Receives FDA Fast Track Designation for Diacerein 1% Ointment for Treatment of Epidermolysis Bullosa Simplex
Castle Creek Pharmaceuticals, LLC., a US-based company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the U.S. Food & Drug Administration (FDA) has designated as a Fast Track development program the investigation of diacerein 1%, ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS).
Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment
Castle Creek Pharmaceuticals, LLC., a US-based company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the U.S. Food & Drug Administration (FDA) has designated as a Fast Track development program the investigation of diacerein 1%, ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS).
Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa
Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB).
Subscribe
Sign up with your email address to receive news and updates.
We respect your privacy.